Literature DB >> 26123599

Trastuzumab in metastatic breast cancer after complete remission: How long is enough?

Arzu Oguz1, Samed Rahatli, Ozden Altundag, Kadri Altundag.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26123599     DOI: 10.1007/s12032-015-0648-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  4 in total

1.  Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review.

Authors:  Min Yan; Hui-Min Lv; Meng-Wei Zhang; Shu-De Cui
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

2.  Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.

Authors:  Filippo Montemurro; Aleix Prat; Valentina Rossi; Giorgio Valabrega; Jeff Sperinde; Caterina Peraldo-Neia; Michela Donadio; Patricia Galván; Anna Sapino; Massimo Aglietta; José Baselga; Maurizio Scaltriti
Journal:  Mol Oncol       Date:  2013-09-13       Impact factor: 6.603

3.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Authors:  Sandra M Swain; José Baselga; Sung-Bae Kim; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Sarah Heeson; Emma Clark; Graham Ross; Mark C Benyunes; Javier Cortés
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

Review 4.  Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.

Authors:  Isabel Ihnenfeld Arciénega; Patrick Imesch; Daniel Fink; Konstantin J Dedes
Journal:  Target Oncol       Date:  2014-12-17       Impact factor: 4.493

  4 in total
  1 in total

1.  Trastuzumab in metastatic breast cancer after complete remission: an expensive commitment for an entire life?

Authors:  D Bernardi; M Stefani; M Boccalon; C Raiti
Journal:  Curr Oncol       Date:  2017-02-27       Impact factor: 3.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.